Literature DB >> 6123782

Treatment of neuroleptic malignant syndrome with dantrolene.

J G Goekoop, P A Carbaat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6123782     DOI： 10.1016/s0140-6736(82)91189-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Neuroleptic malignant syndrome.

Authors:  T H Lee; L M Tang
Journal:  J Neurol       Date:  1988-05       Impact factor: 4.849

2.  Neuroleptic malignant syndrome: a review.

Authors:  R A O'Brien; G B Young
Journal:  Can Fam Physician       Date:  1989-05       Impact factor: 3.275

3.  Neuroleptic malignant syndrome: another medical cause of acute abdomen.

Authors:  T C Lo; M R Unwin; I W Dymock
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

Review 4.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

5.  Postoperative malignant hyperthermia and dantrolene therapy.

Authors:  U Schulte-Sasse; W Hess; H J Eberlein
Journal:  Can Anaesth Soc J       Date:  1983-11

Review 6.  Neuroleptic malignant syndrome.

Authors:  M S Jahan; A I Farooque; Z Wahid
Journal:  J Natl Med Assoc       Date:  1992-11       Impact factor: 1.798
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.